Old Articles: <Older 7791-7800 Newer> |
|
The Motley Fool August 11, 2011 Seth Jayson |
A Hidden Reason the Future Looks Bright for Baxter International What's going on with the inventory at Baxter International? I chart the details below for both quarterly and 12-month periods. |
The Motley Fool August 10, 2011 Evan Niu |
One Medical-Device Stock to Buy MAKO Surgical delivers strong results. |
The Motley Fool August 10, 2011 Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
The Motley Fool August 10, 2011 Brian Orelli |
A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects. |
Fast Company August 8, 2011 Kate Rockwood |
AIDS Vaccine Conference Despite billions in annual research dollars, the quest for an AIDS vaccine remains elusive. |
The Motley Fool August 10, 2011 Brandon Glenn |
Athersys More Threatened Than Most by Falling Share Price Recent market movements have been brutal for small biotech Athersys. |
The Motley Fool August 9, 2011 Brian Orelli |
Give Avanir Some Time It's going to need it. |
Pharmaceutical Executive August 1, 2011 William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
Pharmaceutical Executive August 1, 2011 |
Employers: Fighting Non-Adherence A Q and A with Andrew Webber, President and CEO of the National Business Coalition on Health |
Pharmaceutical Executive August 1, 2011 Jennifer Ringler |
The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout? |
<Older 7791-7800 Newer> Return to current articles. |